These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 39217520

  • 21. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
    Chu CE, Cowan JE, Lonergan PE, Washington SL, Fasulo V, de la Calle CM, Shinohara K, Westphalen AC, Carroll PR.
    Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
    [Abstract] [Full Text] [Related]

  • 22. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S, de Cobelli O, Cozzi G, Peveri G, Bagnardi V, Catellani M, Di Trapani E, Mistretta FA, Pricolo P, Conti A, Alessi S, Marvaso G, Ferro M, Matei DV, Renne G, Jereczek-Fossa BA, Petralia G, Musi G.
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [Abstract] [Full Text] [Related]

  • 23. MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.
    Boschheidgen M, Schimmöller L, Radtke JP, Kastl R, Jannusch K, Lakes J, Drewes LR, Radke KL, Esposito I, Albers P, Antoch G, Ullrich T, Al-Monajjed R.
    Eur Radiol; 2024 Sep 13. PubMed ID: 39269474
    [Abstract] [Full Text] [Related]

  • 24. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D, Gromicho A, Dias J, Bastos S, Maciel RM, Sabença A, Xambre L.
    Arch Ital Urol Androl; 2023 Dec 20; 95(4):11830. PubMed ID: 38117217
    [Abstract] [Full Text] [Related]

  • 25. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM, Moser S, Hepp T, Kruck S, Rausch S, Scharpf M, Nikolaou K, Stenzl A, Bedke J, Kaufmann S.
    World J Urol; 2022 Oct 20; 40(10):2431-2438. PubMed ID: 35922717
    [Abstract] [Full Text] [Related]

  • 26. Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.
    Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, Delprado W, Lee J, Thompson JE, Cusick T, Spriensma AS, Siriwardana AR, Yuen C, Kooner R, Hruby G, O'Neill G, Emmett L.
    BJU Int; 2019 Nov 20; 124 Suppl 1():42-49. PubMed ID: 31287613
    [Abstract] [Full Text] [Related]

  • 27. The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy.
    Nyk Ł, Tayara O, Ząbkowski T, Kryst P, Andrychowicz A, Malewski W.
    BMC Urol; 2021 May 18; 21(1):82. PubMed ID: 34006281
    [Abstract] [Full Text] [Related]

  • 28. Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?
    Porcaro AB, Bianchi A, Panunzio A, Gallina S, Serafin E, Tafuri A, Trabacchin N, Orlando R, Ornaghi PI, Mazzucato G, Vidiri S, D'Aietti D, Montanaro F, Brusa D, Patuzzo GM, Artoni F, Baielli A, Migliorini F, De Marco V, Veccia A, Brunelli M, Siracusano S, Cerruto MA, Antonelli A.
    Int Urol Nephrol; 2024 Aug 18; 56(8):2597-2605. PubMed ID: 38553619
    [Abstract] [Full Text] [Related]

  • 29. Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.
    Li X, Wang ZX, Zhu YP, Wang J, Yin YS, Zeng XY.
    Asian J Androl; 2022 Aug 18; 24(5):487-493. PubMed ID: 35170453
    [Abstract] [Full Text] [Related]

  • 30. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.
    BJU Int; 2017 Oct 18; 120(4):511-519. PubMed ID: 28267899
    [Abstract] [Full Text] [Related]

  • 31. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
    Taghipour M, Ziaei A, Alessandrino F, Hassanzadeh E, Harisinghani M, Vangel M, Tempany CM, Fennessy FM.
    Abdom Radiol (NY); 2019 Apr 18; 44(4):1520-1527. PubMed ID: 30361870
    [Abstract] [Full Text] [Related]

  • 32. Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens.
    Kim H, Jung G, Kim JH, Byun SS, Hong SK.
    Sci Rep; 2021 Aug 31; 11(1):17447. PubMed ID: 34465825
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer.
    Esen B, Seymen H, Gurses B, Armutlu A, Koseoglu E, Tarim K, Ertoy Baydar D, Sarikaya AF, Canda AE, Balbay D, Kordan Y, Tilki D, Esen T, Demirkol MO.
    Prostate; 2024 Jan 31; 84(1):32-38. PubMed ID: 37661579
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
    Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR.
    J Urol; 2019 Feb 31; 201(2):300-307. PubMed ID: 30179620
    [Abstract] [Full Text] [Related]

  • 38. Complementing the active surveillance criteria with multiparametric magnetic resonance imaging.
    Kim TU, Baek SR, Song WH, Nam JK, Lee HJ, Park SW.
    Investig Clin Urol; 2020 Nov 31; 61(6):573-581. PubMed ID: 33135402
    [Abstract] [Full Text] [Related]

  • 39. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
    Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Roumiguié M, Fossati N, Stabile A, Beauval JB, Malavaud B, Scuderi S, Barletta F, Moschini M, Zamboni S, Rakauskas A, Tian Z, Karakiewicz PI, De Cobelli F, Porpiglia F, Montorsi F, Briganti A.
    Eur Urol; 2020 Jun 31; 77(6):733-741. PubMed ID: 31547938
    [Abstract] [Full Text] [Related]

  • 40. Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?
    Mazzone E, Stabile A, Sorce G, Pellegrino F, Barletta F, Motterle G, Scuderi S, Cirulli GO, Cucchiara V, Brembilla G, Esposito A, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Karnes RJ, Guccini I, Briganti A.
    Urol Oncol; 2021 Nov 31; 39(11):784.e1-784.e9. PubMed ID: 33865687
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.